KBC Group’s Soleno Therapeutics SLNO Stock Holding History

KBC Group’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,367	Closed	-$46K	–	1877
2026 Q1	$46K	Hold	1,367	–	–	﹤0.01%	1681
2025 Q4	$63K	Hold	1,367	–	–	﹤0.01%	1553
2025 Q3	$92K	Buy	1,367 +450	+49%	+$33.4K	﹤0.01%	1319
2025 Q2	$77K	Buy	+917	New	+$68.6K	﹤0.01%	1378

KBC Group's SLNO Position: Q2 2026 in Review

KBC Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 1,367 shares — an estimated $46K sold.

KBC Group first reported a position in SLNO in Q2 2025 and held it in 4 quarters. The position peaked at $92K in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

KBC Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
KBC Group sold 1,367 Soleno Therapeutics shares in Q2 2026, an estimated $46K.
KBC Group first reported a position in Soleno Therapeutics in Q2 2025 and held it in 4 quarters.
KBC Group's Soleno Therapeutics position peaked at $92K in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.